


PF-573228

Cat. No.:	HY-10461		
CAS No.:	869288-64-2		
Molecular Formula:	C ₂₂ H ₂₀ F ₃ N ₅ O ₃ S		
Molecular Weight:	491.49		
Target:	FAK; Apoptosis		
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 51 mg/mL (103.77 mM)
 H₂O : < 0.1 mg/mL (insoluble)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.0346 mL	10.1731 mL	20.3463 mL
	5 mM	0.4069 mL	2.0346 mL	4.0693 mL
	10 mM	0.2035 mL	1.0173 mL	2.0346 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.5 mg/mL (5.09 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.08 mg/mL (4.23 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PF-573228 is a potent and selective FAK inhibitor with IC₅₀ of 4 nM for purified recombinant catalytic fragment of FAK.

IC₅₀ & Target

IC₅₀: 4 nM (FAK)^[1]

In Vitro

PF-573228 inhibits purified recombinant catalytic fragment of FAK with an IC₅₀ of 4 nM. In cultured cells, PF-573228 inhibits

FAK phosphorylation on Tyr₃₉₇ with an IC₅₀ of 30-100 nM. Treatment of cells with concentrations of PF-573228 that significantly decreased FAK Tyr₃₉₇ phosphorylation fails to inhibit cell growth or induce apoptosis. In contrast, treatment with PF-573228 inhibits both chemotactic and haptotactic migration concomitant with the inhibition of focal adhesion turnover^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay ^[1]

Purified activated FAK kinase domain is reacted with 50 μM ATP, and 10 μg/well of a random peptide polymer of Glu and Tyr (molar ratio of 4:1), poly (Glu/Tyr) in kinase buffer for 15 min. Phosphorylation of poly(Glu/Tyr) is challenged with s
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay ^[1]

REF52 or PC3 cells are seeded into a 24-well plate in triplicate 24 h prior to daily treatment with the indicated concentrations of each inhibitor (PF-573228) for 3 days. Subsequently, the cells are harvested and counted. Apoptosis assays are performed using a cell death detection ELISA. REF52, PC3 or MDCK cells are treated for 24 h (16 h for MDCK) with the indicated concentrations of each inhibitor prior to lysis. Cells suspended for 16-24 h in serum-free medium served as a positive control. The cell lysates are incubated in duplicate in the ELISA system. The data represent the means±standard deviation of one of three experiments performed in duplicate^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Adv Sci. 2020 Jun 17;7(15):1903583.
- Biomaterials. 2018 Oct 15;188:130-143.
- Biomaterials. 2018 Sep;178:281-292.
- Cell Adh Migr. 2017 Jul 4;11(4):327-337.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Slack-Davis JK, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA